Penumbra, Inc.
NYSE:PENMedical - Devices
-$2.30 today
- Market cap
- $12.64B
- Beta
- 0.70
- P/E (TTM)
- 72.6
- EPS (TTM)
- $4.36
Volume 0.21M
Average 0.50M
PEN Common Stock Issued
Cash raised by issuing new shares.
Penumbra, Inc.NYSE: PEN
Common Stock Issued · Q2 FY2026 · quarter ended Jun 2026
Common stock issued declines year over year
Q2 FY2026 common stock issued of $9.67M fell 37.9% year over year, behind the -20.8% change in trailing-twelve-month common stock issued. Over 3 fiscal years it compounded at +13.9% a year.
Context
- Common stock issued amounted to 2.3% of revenue in FY2025, up 0.8 pp from a year earlier.
- Common stock issued increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -37.9% toward the trailing-twelve-month pace of -20.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 31.82M USD
- Year-over-year change
- +85.3%
- 4-year CAGR
- +14.7%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.82M | +85.3% |
| FY2024 | 2024-12-31 | 17.17M | -15.9% |
| FY2023 | 2023-12-31 | 20.41M | -5.3% |
| FY2022 | 2022-12-31 | 21.55M | +17.3% |
| FY2021 | 2021-12-31 | 18.37M | — |
Common Stock Issued vs competitors
How PEN compares with its peers on the latest reported figures
- PEN's LTM Jun 2026 common stock issued of $21.87M is the 6th largest of the 9 companies compared; the peer median is $174M.
- Its year-over-year change of -20.8% is the 7th highest of 9, against a peer median of -4.0%.
- Common stock issued amounts to 1.5% of revenue for PEN, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $441M | -14.2% | +18.8% | 1.2% | |
| LTM Sep 2026 | $360.4M | +7.4% | — | 3.1% | |
| LTM Jun 2026 | $221M | -18.5% | — | 1.1% | |
| LTM Jun 2026 | $193M | -40.1% | — | 0.4% | |
| LTM Jun 2026 | $155M | +44.7% | — | 2.4% | |
| LTM Jun 2026 | $21.87M | -20.8% | +13.9% | 1.5% | |
| LTM Mar 2026 | $8M | +272.9% | +25.3% | 3.1% | |
| LTM Sep 2026 | $6.03M | -87.3% | +12.0% | 0.4% | |
| LTM Feb 2026 | $950K | +6.1% | — | 0.3% | |
| Peer median (excluding PEN) | $174M | -4.0% | +18.8% | 1.1% | |
Competitors are the stored peer set for PEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 5.28M | (2M) | 90.95M | 14.01M | 177.69M |
| Depreciation & Amortization | 16.41M | 24.32M | 27.26M | 23.7M | 17.47M |
| Deferred Income Tax | (14.09M) | 1.46M | (19.06M) | (16.34M) | 21.03M |
| Stock-Based Compensation | 0 | 0 | 0 | 46.16M | 59.21M |
| Change in Working Capital | (66.71M) | (121.54M) | (79.08M) | (23.78M) | (42.72M) |
| Accounts Receivables | (21.34M) | (69.86M) | (266K) | 26.6M | (19.51M) |
| Inventory | (51.55M) | (74.63M) | (67.71M) | (65.66M) | (26.48M) |
| Accounts Payables | (1.57M) | 13.39M | 1.1M | 4.17M | 3.07M |
| Other Working Capital | 7.75M | 9.57M | (12.21M) | 11.11M | 213K |
| Other Non-Cash Items | 68.61M | 42.1M | 77.27M | 124.72M | 5.97M |
| Operating Cash Flow | 9.5M | (55.66M) | 97.33M | 168.48M | 238.66M |
| Capital Expenditures | (21.18M) | (19.3M) | (15.21M) | (21.18M) | (63.73M) |
| Acquisitions (Net) | 2.92M | 0 | (988K) | 0 | 0 |
| Purchases of Investments | (126.79M) | 0 | (81.94M) | (32.91M) | (355.74M) |
| Sales of Investments | 123.72M | 74.09M | 82.57M | 130.62M | 14.88M |
| Other Investing Activities | (400K) | 0 | (500K) | 1.1M | 0 |
| Investing Cash Flow | (21.74M) | 54.79M | (16.08M) | 77.62M | (404.59M) |
| Debt Repayment | (1.45M) | (1.75M) | (1.98M) | (2.28M) | (2.49M) |
| Common Stock Issued | 18.37M | 21.55M | 20.41M | 17.17M | 31.82M |
| Common Stock Repurchased | 0 | 0 | 0 | (100.39M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (16.08M) | (8.18M) | (2.23M) | (1.52M) | (2.8M) |
| Financing Cash Flow | 836K | 11.62M | 16.2M | (87.01M) | 26.53M |
| Effect of Forex Changes | 1.11M | (272K) | 168K | (2.18M) | 1.89M |
| Net Change in Cash | (10.29M) | 10.48M | 97.63M | 156.92M | (137.51M) |
| Free Cash Flow | (11.68M) | (74.96M) | 82.12M | 147.3M | 174.93M |
Penumbra, Inc.
NYSE:PEN
Intrinsic Alpha fair value
Locked
Current Price
$320.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.